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warranted to identify steps for increasing treatment 
effectiveness in these patients.
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OBJECTIVES: Prior results from the TACTICS-TIMI 
18 trial demonstrated that an early invasive approach 
to the management of patients with unstable angina 
(UA) or non-ST-segment elevation myocardial infarction
(NSTEMI) was cost-effective, with an estimated cost per
life-year gained of $8371; for high-risk patients with ST-
segment changes at baseline, $3224 per life-year gained.
We examined the joint inﬂuence of diabetes and ST-
segment changes on the cost-effectiveness of the early
invasive strategy. METHODS: Inpatient hospital costs for
the 1722 US, non-VA patients for the 6-month trial
period were obtained from the UB92 and Medicare
cost/charge ratios. Other costs included: physician, 
outpatient, medication, and productivity costs. Life-
expectancy estimates for patients with acute MI/coronary
heart disease from the Framingham Heart Study were
used for patients who survived the trial with/without
experiencing a non-fatal MI. Cost-effectiveness was eval-
uated in terms of cost per life-year gained. Regression
analyses of the net monetary beneﬁt across a range of
ceiling ratios were used to obtain cost-effectiveness
acceptability curves for subgroups deﬁned by diabetes
and ST-change status. RESULTS: Net monetary beneﬁt
regression analyses revealed a three-way interaction
between diabetes, ST-changes and treatment group which
approached signiﬁcance (p < 0.10) for models based on a
ceiling ratio of $14,000–$49,000. Associated cost-
effectiveness acceptability curves suggest a probability
that the invasive strategy is cost-effective for non-diabetic
patients with ST-segment changes of >95% for ceiling
ratios $4000 per life-year gained. At a ceiling ratio of
$50,000, the probability of cost-effectiveness for diabetic
patients without ST-changes is 56%, for diabetic patients
with ST-changes, 73%, and for non-diabetic patients
without ST-changes, 74%. CONCLUSIONS: In addi-
tion to ST-segment changes at presentation, the cost-
effectiveness of an invasive strategy for patients with UA
or NSTEMI varies by DM status. This analysis demon-
strates the usefulness and efﬁciency of net-beneﬁt regres-
sion for the evaluation of cost-effectiveness for different
patient subgroups.
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OBJECTIVES: To compare the effectiveness of two
widely prescribed agents, amlodipine and valsartan, in
blood pressure lowering and control in a multi-center
ambulatory practice setting. METHODS: All adult hyper-
tensive patients were identiﬁed from 1998 to 2001 from
a large commercially available electronic medical record
covering over 360,000 US primary care patients. Study
patients were required to have initiated therapy with
either amlodipine or valsartan and to have at least one
BP measurement within 6 months preceding and 12
months following the index date. Mean change in systolic
blood pressure (SBP) and rates of JNC VI BP goal 
attainment were compared using multivariate statistics.
RESULTS: One thousand one hundred seventy-ﬁve
amlodipine and 512 valsartan patients met criteria. Base-
line SBP was 159.5mmHg for amlodipine; 159.9 for 
valsartan. Overall, amlodipine was associated with 
an adjusted mean change of -16.6mmHg in SBP (95%
CI-17.7, -15.5) vs. -13.4mmHg for valsartan (95% 
CI-15.1, -11.7; p = 0.002). Approximately 43% of
amlodipine patients achieved JNC VI goal vs. 33% in the
valsartan treated cohort (p = 0.030). Among patients on
complex antihypertensive regimens (2 or more agents),
amlodipine was associated with an adjusted mean change
of -16.6mmHg (95% CI -18.5, -14.8) vs. -10.0mmHg
for valsartan (95% CI -12.8, -7.2; p < 0.001). Within
this subgroup, JNC VI goal attainment was 43% vs. 36%
for amlodipine vs. valsartan (p = 0.095). CONCLU-
SIONS: In monotherapy and in combination, amlodipine
demonstrated both a statistically signiﬁcant and clinically
meaningful improvements in SBP change and JNC VI goal
attainments vs. valsartan, particularly among patients on
complex antihypertensive regimens. Although these data
must be interpreted within the limitations of the obser-
vational study design, this study suggests that amlodipine
may be used in a variety of therapeutic combinations 
and among a broad spectrum of hypertensive adults to
improve SBP control and goal attainment.
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